Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania

Mosha, Fausta; Ledwaba, Johanna; Ndugulile, Faustine; Ng'ang'a, Zipora; Nsubuga, Peter; Morris, Lynn; Kasubi, Mabula; Swai, Andrew; Vercauteren, Jurgen; Vandamme, Anne-Mieke
July 2014
Journal of Infection in Developing Countries;Jul2014, Vol. 8 Issue 7, p845
Academic Journal
Introduction: In Tanzania, the follow-up on antiretroviral therapy (ART) response is based on clinical outcomes. We investigated virological response and ARV resistance mutations in relation to clinical response in ARV-treated patients. Methodology: A cross-sectional study of a cohort of 150 patients taking first-line ART in Dar-es-Salaam was conducted. Data were collected using standardized questionnaires and patients' blood samples. HIV viral load testing and genotyping was performed on all viremic samples. Statistical analyses compared clinical responders and non-responders. Results: The median time on ART was 20 months; 71 (47%) patients were ART clinical responders. Clinical non-responders were more likely to have started ART with advanced disease with significantly lower median percentage weight gain (6% versus 20%) with respect to pre-treatment levels. Sixty-one (86%) and 64 (81%) of clinical responders and non-responders, respectively, had undetectable viral loads. Genotyping was successful in 24 (96%) virologically failing patients, among whom 83% had resistance mutations; 67% had dual nucleoside reverse transcriptase inhibitor (NRTI)/non-NRTI (NNRTI) resistance mutations. Seventeen (71%) and 19 (79%) patients had NRTI and NNRTI resistance mutations, respectively, which were related to the ART in use, with no difference between clinical responders and non- responders. The most prevalent subtypes were A and C, found in 9 (38%) and 7 (29%) patients, respectively. Conclusions: The observed virological response was high and did not correlate with clinical response. The prevalence of ARV resistance mutations was high in viraemic patients and was related to the ARV prescribed. We recommend use of viral load monitoring during ART in Tanzania.


Related Articles

  • Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study. Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm³...

  • A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. Girard, Pierre-Marie; Cabié, André; Michelet, Christian; Verdon, Renaud; Katlama, Christine; Mercié, Patrick; Morand-Joubert, Laurence; Pétour, Pascal; Monchecourt, Françoise; Chêne, Geneviève; Trylesinski, Aldo // Journal of Antimicrobial Chemotherapy (JAC);Jul2009, Vol. 64 Issue 1, p126 

    Objectives To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection. Methods A non-inferiority, randomized, multicentre, open-label trial was performed in 24 AIDS clinical centres in France...

  • Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine. Anthony Amoroso; Bruce Gilliam; Rohit Talwani; Colleen Boyce; Robert Redfield; Charles Davis // HIV Clinical Trials;Sep2009, Vol. 10 Issue 5, p320 

    Purpose: The once-daily nucleoside reverse transcriptase inhibitor backbone of tenofovir and emtricitabine has been proven effective in combination with efavirenz and protease inhibitors in large clinical trials. This study evaluated tenofovir and emtricitabine in combination with nevirapine....

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool. Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on antiretroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL...

  • Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Ghate, Manisha; Tripathy, Srikanth; Gangakhedkar, Raman; Thakar, Madhuri; Bhattacharya, Jayanta; Choudhury, Ipsita; Risbud, Arun; Bembalkar, Shilpa; Kadam, Dileep; Rewari, Bharat B.; Paranjape, Ramesh // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p942 

    Background & objectives: The treatment outcomes under national antiretroviral therapy (ART) programme are being evaluated in some ART centres in the country. We carried out this study to analyze the impact of first line antiretroviral therapy in HIV infected patients attending a free ART roll...

  • Hospitalized HIV-Infected Patients in the HAART Era: A View from the Inner City. Pulvirenti, Joseph J.; Glowacki, Robert; Muppiddi, Uma; Surapaneni, Neelima; Gail, Cheri; Kohl, Becky; Jezisek, Todd // AIDS Patient Care & STDs;Nov2003, Vol. 17 Issue 11, p565 

    To evaluate hospitalizations of HIV-infected patients in the highly active antiretroviral therapy (HAART) era, we analyzed 2736 admissions of 1562 HIV-infected patients to Cook County Hospital from September 20, 1999 to July 10, 2002. Patients were predominantly African American (81%), male...

  • Recent HIV-1 Infection: To Treat or Not to Treat, That Is the Question. Tossonian, Harout; Conway, Brian // Journal of Infectious Diseases;1/1/2012, Vol. 205 Issue 1, p10 

    The author reflects on a study conducted by C. Hogan and colleagues' setpoint study, a randomized clinical trial in which patients who had been infected with HIV in the previous six months were assigned to receive a 36-week course of antiretroviral therapy. The study's principal end point was a...

  • Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic Consequences. Mata, Rosario C.; Viciana, Pompeyo; de Alarcón, Arístides; López-Cortés, Luis F.; Gómez-Vera, Josefa; Trastoy, Mónica; Cisneros, José M. // AIDS Patient Care & STDs;Sep2005, Vol. 19 Issue 9, p550 

    To investigate the clinical, virologic and immunologic consequences of planned treatment interruptions in chronically HIV-infected patients. One hundred forty-one patients with undetectable viral load for at least 6 months and CD4+ T cells count greater than 500 per microliter were recruited....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics